Business
Calidi Bio partners with TransferAI on agentic AI for CLD-401 IND submission
Calidi Biotherapeutics (NYSE American: CLDI) has entered a collaboration with TransferAI, a private Austin-based AI company, to apply agentic AI...
AstraZeneca licenses Pinetree Therapeutics EGFR degrader program for USD 25m option exercise
AstraZeneca (NYSE: AZN) has exercised its option to license Pinetree Therapeutics' EGFR degrader program, converting a preclinical option agreement into a...
Veradermics to debut on NYSE for USD 384.4m to advance pattern hair loss therapeutic development
Veradermics (NYSE: Mane), a New Haven, Connecticut-based late clinical-stage biopharmaceutical company focused on pattern hair loss therapeutics, announced...
AstraZeneca's Q1'26 Earnings Call: Mixed messages for tozorakimab, efzimfotase alfa
AstraZeneca's Q1 2026 earnings conference call, held on April 29, 2026, was dominated by three converging pipeline signals: a historic triple Phase III...
Astellas Pivots Away from XTANDI, Betting Big on KRAS Degraders and Gene Therapy
Astellas Pharma's Q4 FY2025 earnings call, held April 27, 2026, revealed a company accelerating its transition away from XTANDI dependence through a...
Germany-based mbiomics completes Series A third closing at EUR 30m for microbiome therapeutics
Munich-based mbiomics GmbH has completed a third closing of its Series A round, bringing total financing to EUR 30 million. The latest tranche added EUR 12...
Coultreon Biopharma raises USD 125m Series A to advance oral SIK3 inhibitor
Leuven-based Coultreon Biopharma, formerly known as Onco3R Therapeutics, has closed a USD 125 million Series A financing round to advance its immunology...
Lighthouse Pharmaceuticals closes USD 12m Series A for Alzheimer's drug trial
Novato, California-based Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company focused on small-molecule therapies for neurodegenerative...
Chiesi Group acquires KalVista for USD 1.9b, expanding rare disease portfolio with Ekterly
Italy-based Chiesi Group has agreed to acquire Framingham, Massachusetts-based KalVista Pharmaceuticals (Nasdaq: KALV) for USD 27.00 per share in cash,...
Sagimet Biosciences raises USD 175m Series A offering for acne therapeutics
Sagimet Biosciences (NASDAQ: SGMT), a clinical-stage biopharmaceutical company based in San Mateo, California focused on therapeutics targeting...
Fathom Therapeutics raises USD 47m in Series A for AI-enabled small molecule drug design
New York-based Fathom Therapeutics, formerly known as Atommap Corp., has closed an oversubscribed USD 47 million Series A financing round to advance its...
Vivacta Biotechnology closes USD 50m Series A and A+ funding for CAR-T therapies
Shanghai-based Vivacta Biotechnology (Shanghai) Co., Ltd. has closed combined Series A and Series A+ financing totaling over USD 50 million to advance its...
Teva acquires Emalex Biosciences in USD 900m deal for ecopipam
Teva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) has agreed to acquire Chicago-based Emalex Biosciences for USD 700 million upfront, plus up to USD...
AbbVie secures exclusive option to acquire Kestrel Therapeutics for USD 1.45b for pan-KRAS inhibitor KST-6051
AbbVie has entered into a warrant agreement with Watertown, Massachusetts-based Kestrel Therapeutics, granting AbbVie an exclusive option to acquire the...
Artelo Biosciences partners with ScienceMachine to apply AI technology to FABP5 inhibitor program
Artelo Biosciences (Nasdaq: ARTL) has entered a strategic collaboration with AI platform company ScienceMachine to apply machine learning to its fatty...
The AllSci Brief
Systematic R&D and deal news. Daily.